JP3308534B2 - 新規なサイトカイン - Google Patents

新規なサイトカイン

Info

Publication number
JP3308534B2
JP3308534B2 JP50789793A JP50789793A JP3308534B2 JP 3308534 B2 JP3308534 B2 JP 3308534B2 JP 50789793 A JP50789793 A JP 50789793A JP 50789793 A JP50789793 A JP 50789793A JP 3308534 B2 JP3308534 B2 JP 3308534B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
cells
amino acids
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50789793A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07504083A (ja
Inventor
アーミテイジ，リチャード・ジェイ
ファンスロウ，ウィリアム・シー
スプリッグス，メラニー・ケイ
スリニヴァッサン，サブハッシニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3308534(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of JPH07504083A publication Critical patent/JPH07504083A/ja
Application granted granted Critical
Publication of JP3308534B2 publication Critical patent/JP3308534B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP50789793A 1991-10-25 1992-10-23 新規なサイトカイン Expired - Fee Related JP3308534B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
US805,723 1991-12-05
US783,707 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP9318110A Division JP2877788B2 (ja) 1991-10-25 1997-11-19 新規なサイトカインに対する抗体

Publications (2)

Publication Number Publication Date
JPH07504083A JPH07504083A (ja) 1995-05-11
JP3308534B2 true JP3308534B2 (ja) 2002-07-29

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50789793A Expired - Fee Related JP3308534B2 (ja) 1991-10-25 1992-10-23 新規なサイトカイン
JP9318110A Expired - Lifetime JP2877788B2 (ja) 1991-10-25 1997-11-19 新規なサイトカインに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP9318110A Expired - Lifetime JP2877788B2 (ja) 1991-10-25 1997-11-19 新規なサイトカインに対する抗体

Country Status (12)

Country Link
EP (2) EP0897983B1 (cg-RX-API-DMAC7.html)
JP (2) JP3308534B2 (cg-RX-API-DMAC7.html)
KR (1) KR100283541B1 (cg-RX-API-DMAC7.html)
AT (2) ATE274055T1 (cg-RX-API-DMAC7.html)
AU (1) AU661360B2 (cg-RX-API-DMAC7.html)
CA (2) CA2312667C (cg-RX-API-DMAC7.html)
DE (2) DE69233402T3 (cg-RX-API-DMAC7.html)
DK (3) DK0897983T3 (cg-RX-API-DMAC7.html)
ES (2) ES2198025T3 (cg-RX-API-DMAC7.html)
FI (2) FI116850B (cg-RX-API-DMAC7.html)
NO (2) NO317625B1 (cg-RX-API-DMAC7.html)
WO (1) WO1993008207A1 (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ATE256180T1 (de) * 1993-01-22 2003-12-15 Immunex Corp Detektion und behandlung von mutationen in einem gen für einen cd40-liganden
EP0612529B1 (en) * 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
EP0742721B1 (en) * 1993-09-02 1999-05-06 Trustees of Dartmouth College Methods of prolonged suppression of humoral immunity
CN100341896C (zh) 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
CA2213798C (en) * 1995-03-01 2001-02-06 Immunex Corporation Method for stimulating an immune response
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
KR100453314B1 (ko) * 1995-06-07 2004-12-17 임뮤넥스 코포레이션 Cd40l 돌연변이 단백질
DK0833847T3 (da) * 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
AU3570797A (en) * 1996-06-14 1998-01-07 University Of Washington Absorption-enhanced differential extraction device
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
IL127912A0 (en) * 1996-07-10 1999-11-30 Immunex Corp Method of activating dendritic cells
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6017729A (en) 1996-12-23 2000-01-25 Immunex Corporation Receptor activator of NF-κB
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ES2317694T3 (es) 1998-05-14 2009-04-16 Immunex Corporation Metodo para inhibir la actividad osteoclastica.
ME00238B (me) 1998-10-23 2011-02-10 Kirin Amgen Inc Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
IL144952A0 (en) * 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
NO345566B1 (no) 2001-06-26 2021-04-19 Amgen Inc OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
JP2006517802A (ja) 2003-02-14 2006-08-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 外来性分子の一過性の発現もしくは安定な発現のための発現カセットおよび発現ベクター
BRPI0513798A (pt) 2004-07-26 2008-05-13 Biogen Idec Inc anticorpos anti-cd154
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
MX345141B (es) 2006-09-13 2017-01-18 Abbvie Inc * Mejoras de cultivos celulares.
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
EP4512422A3 (en) 2007-09-14 2025-05-21 Amgen Inc. Homogenous antibody populations
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
HUE047164T2 (hu) 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
NZ586576A (en) 2008-01-15 2012-08-31 Abbott Lab Improved mammalian expression vectors and uses thereof
EP3255153A1 (en) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Methods for enhanced protein production
NO2525817T3 (cg-RX-API-DMAC7.html) 2010-01-21 2018-01-06
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AR095313A1 (es) 2013-03-15 2015-10-07 Univ Arkansas Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
CN115873904A (zh) 2016-05-11 2023-03-31 美国安进公司 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞
CN110381974A (zh) * 2017-02-27 2019-10-25 沙塔克实验室有限公司 基于csf1r的嵌合蛋白
MX2019009812A (es) 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
NO941422D0 (no) 1994-04-19
AU661360B2 (en) 1995-07-20
FI981765A0 (fi) 1998-08-17
EP0667901B2 (en) 2008-10-15
NO941422L (cg-RX-API-DMAC7.html) 1994-06-27
ATE274055T1 (de) 2004-09-15
JP2877788B2 (ja) 1999-03-31
NO317625B1 (no) 2004-11-29
CA2312667C (en) 2002-11-19
NO980030L (no) 1998-01-05
KR100283541B1 (ko) 2001-03-02
ES2198025T3 (es) 2004-01-16
DE69233051T2 (de) 2004-03-11
CA2312667A1 (en) 1993-04-29
FI116850B (fi) 2006-03-15
EP0897983B1 (en) 2003-05-07
EP0667901B1 (en) 2004-08-18
CA2121798C (en) 2007-07-24
DE69233051D1 (de) 2003-06-12
NO320073B1 (no) 2005-10-17
JPH07504083A (ja) 1995-05-11
NO980030D0 (no) 1998-01-05
DK0667901T4 (da) 2008-11-10
DK0667901T3 (da) 2004-12-27
DK0822199T3 (da) 2004-12-27
EP0897983A3 (en) 1999-03-17
EP0667901A1 (en) 1995-08-23
DE69233402T3 (de) 2009-06-25
EP0897983A2 (en) 1999-02-24
EP0667901A4 (en) 1995-06-22
ATE239790T1 (de) 2003-05-15
AU3122693A (en) 1993-05-21
DK0897983T3 (da) 2003-08-11
WO1993008207A1 (en) 1993-04-29
FI941837A0 (fi) 1994-04-20
FI981765L (fi) 1998-08-17
DE69233402T2 (de) 2005-09-15
CA2121798A1 (en) 1993-04-29
HK1019343A1 (en) 2000-02-03
FI941837L (fi) 1994-05-30
JPH10150994A (ja) 1998-06-09
ES2227513T3 (es) 2005-04-01
FI116828B (fi) 2006-03-15
DE69233402D1 (de) 2004-09-23
ES2227513T5 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
JP3308534B2 (ja) 新規なサイトカイン
US7309489B1 (en) Mouse CD40 ligand-specific antibodies and hybridomas
US6410711B1 (en) DNA encoding CD40 ligand, a cytokine that binds CD40
EP0615451B1 (en) Novel cytokine that binds cd30
JP3559281B2 (ja) Ｃｄ２７リガンド
US6355779B1 (en) Cytokine designated 4-1BB ligand antibodies and human receptor that binds thereto
US5962406A (en) Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US6362325B1 (en) Murine 4-1BB gene
EP0475746B1 (en) Human and murine interleukin-5 receptor
EP0669929B1 (en) Elk ligand, a cytokine
US6274117B1 (en) Cytokines that bind the cell surface receptor Hek
AU694232B2 (en) Receptor for oncostatin M
US7138500B1 (en) Antibodies to human 4-1BB
EP0739350B1 (en) Ligand that binds fas antigen
WO1994026290A1 (en) Cytokine designated 4-1bb ligand and human receptor that binds thereto
US7405270B2 (en) CD40-Ligand lacking native-pattern glycosylation
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE
US20060063923A1 (en) 4-1BB peptides and methods for use
HK1019343B (en) Antibody against cd40-l

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090517

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100517

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees